Enanta Pharmaceuticals aims to price initial public offering of stock

J.P. Morgan, Credit Suisse, Leerink Swann and JMP Securities assist

By Devika Patel

Knoxville, Tenn., Nov. 6 - Enanta Pharmaceuticals, Inc. intends to price an initial public offering of its common stock, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq exchange under the symbol "ENTA."

The deal has a greenshoe option.

J.P. Morgan, Credit Suisse, Leerink Swann and JMP Securities are assisting.

Proceeds will be used for studies, clinical development and preclinical development of drug candidates, as well as for research and development activities, working capital and other general corporate purposes. The company may also invest the proceeds in capital preservation investments.

The research and development-focused biotechnology company is based in Watertown, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.